Close mobile menu×
Close mobile menu

Susan E. Bates, MD

Board Certifications: 
Medical Oncology, Internal Medicine
Expertise in: 
Hematology, Pancreatic Cancer, Liver Cancer
Accepting New Patients
Profile Headshot

Appointments

Phone Appointments

New and Existing Patients: 
(212) 305-5098
New Patients: 
(212) 305-5098
Existing Patients: 
(212) 305-9422

myColumbiaDoctors

For existing patients, login to make an appointment, view documentation or contact your care provider.

Credentials & Experience

Board Certifications

  • Medical Oncology
  • Internal Medicine

Clinical Expertise

  • Pancreatic Cancer
  • Liver Cancer
  • Hematology
  • Oncology
  • Chemotherapy
  • Brain Metastases

Education & Training

  • MD, University of Arkansas for Medical Sciences
  • Residency: University of Arkansas Medical Center
  • Residency: Georgetown University Medical Center
  • Fellowship: National Cancer Institute

About Susan Bates

Dr. Susan Bates received her M.D. degree from the University of Arkansas School of Medicine. She completed her clinical training in internal medicine at Georgetown University in Washington, D.C., and in medical oncology at the National Cancer Institute (NCI) in Bethesda, MD. Dr. Bates was a Lead Clinical Investigator and Head of the Molecular Therapeutics Section in the Developmental Therapeutics Branch of the Center for Cancer Research before moving to Columbia University in August 2015.

During her years at the NCI, Dr. Bates led a highly successful translational research program focused on mechanisms of multidrug resistance and approaches to evaluate and improve the activity of epigenetic modifying agents. Her laboratory was among the first to clone the multidrug transporter ABCG2, eventually characterizing its function and its role in chemo-resistance and chemo-protection. This effort built upon earlier work elaborating the role of the multi-drug transporter P-glycoprotein that had defined the drug sensitivity profiles of cell lines in vitro, particularly in the NCI-60 cell line panel. The latter observation continues to impact how the NCI-60 cell line panel is used in drug discovery, and helped her identify a novel agent, at that time known as depsipeptide. Dr. Bates brought this drug to the clinic and after completing its phase I testing, served as Principal Investigator of a multi-institutional, international Phase II study of romidepsin (depsipeptide) in cutaneous and peripheral T-cell lymphoma. Working with Gloucester Pharmaceuticals, the data from this study were included in New Drug Applications (NDA) to the U.S. Food & Drug Administration (FDA). This partnership led to approval by the FDA of romidepsin for two indications - initially for cutaneous T-cell lymphoma and later for peripheral T-cell lymphoma.

Dr. Bates' current interests are both laboratory and clinical in nature. Her laboratory efforts include laboratory and translational studies on drug resistance in T-cell lymphomas and advanced solid tumors including breast, pancreatic, neuroendocrine, renal and lung cancers. Her work is dedicated to new drug development, and finding antineoplastic agents that, alone or in combination with other anticancer agents, improve the options available for difficult to treat cancers. Emanating from the clinical and translational development of romidepsin, a histone deacetylase (HDAC) inhibitor, a current focus is on epigenetic therapies, and the development of combination therapies to use with HDAC inhibitors in refractory advanced cancers, including solid tumors. She also has a special interest in drug delivery and drug distribution and the role of the blood brain barrier in creating a sanctuary site for cancers that metastasize to the brain. Clinically, her goal has always been to translate ideas from the laboratory to clinical trials, an effort that has proven very successful. Clinically she seeks to develop combination therapies with histone deacetylase inhibitors for the therapy of solid tumors; and to develop therapies to treat central nervous system metastases, a complication of cancer that is becoming a greater problem as patients live longer with cancer.

Academic Titles

  • Professor of Medicine at CUMC

Administrative Positions

  • Director, Translational Cancer Medicine

Hospital Affiliations

  • NewYork-Presbyterian/Columbia

Gender

  • Female

Insurance Accepted

Aetna

  • EPO
  • HMO
  • Medicare Managed Care
  • NY Signature
  • POS
  • PPO
  • Signature Administrators
  • Student Health

Affinity

  • Essential Plan
  • Medicaid Managed Care
  • Medicare Managed Care

Amida Care

  • Special Needs Plan

Cigna

  • EPO
  • Great West
  • HMO
  • POS
  • PPO

Emblem/GHI

  • HMO
  • Medicare Managed Care
  • PPO

Emblem/HIP

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Empire Blue Cross Blue Shield

  • Blue Priority
  • EPO
  • HMO
  • Medicare (Mediblue)
  • NYP Employee Plan
  • Pathway (Exchange)
  • POS
  • PPO

Empire Blue Cross Blue Shield HealthPlus

  • Child/Family Health Plus
  • Essential Plan
  • Medicaid Managed Care

Fidelis Care

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Healthfirst

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Local 1199

  • Local 1199

MagnaCare

  • MagnaCare

Multiplan

  • Multiplan

Oxford Health Plans

  • Freedom
  • Liberty
  • Medicare Managed Care

POMCO

  • POMCO

UnitedHealthcare

  • Columbia University Employee Plan
  • Compass (Exchange)
  • EPO
  • Essential Plan
  • HMO
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • POS
  • PPO

VNSNY CHOICE

  • Medicare Managed Care
  • SelectHealth

WellCare

  • Medicaid Managed Care
  • Medicare Managed Care

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Contact & Locations

1
161 Fort Washington Avenue
New York, New York 10032
Phone:
(212) 305-5098
Fax:
(212) 305-6891
Primary

Research

Grants

A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF AG-120 IN PREVIOUSLY-TREATED SUBJECTS WITH NONRESECTABLE OR METASTATIC CHOLANGIOCARCINOMA WITH AN IDH1 MUTATION (P&S Industry Clinical Trial)

Jan 12 2018 - Jan 12 2023